Gout more than doubles the risk for end-stage kidney disease
MONDAY, Sept. 9, 2019 (HealthDay News) — Gout is associated with an elevated risk for chronic kidney disease (CKD) progression, according to a study published online Aug. 28 in BMJ Open.
Austin G. Stack, M.B.B.Ch., M.D., from the University of Limerick in Ireland, and colleagues used data from the U.K. Clinical Practice Research Datalink to identify 68,897 patients with gout and 554,964 matched patients without gout. Adult patients had ≥12 months of clinical data, and the data were linked with Hospital Episode Statistics.
The researchers found that advanced CKD incidence was higher for patients with gout (8.54 per 1,000 patient-years) versus those without gout (4.08 per 1,000 patient-years). In both an unadjusted analysis (hazard ratio [HR], 2.00; 95 percent confidence interval [CI], 1.92 to 2.07) and adjusted analysis (HR, 1.29; 95 percent CI, 1.23 to 1.35), gout was associated with a higher risk for advanced CKD. This association was strongest for end-stage kidney disease (HR, 2.13; 95 percent CI, 1.73 to 2.61) and was evident for estimated glomerular filtration rate <10 mL/min/1.73 m² (HR, 1.45; 95 percent CI, 1.30 to 1.61) and serum creatinine doubling (HR, 1.13; 95 percent CI 1.08 to 1.19). However, the authors observed no correlation between gout and CKD-associated death (HR, 1.14; 95 percent CI, 0.99 to 1.31).
“Future studies should investigate whether controlling gout is protective and reduces CKD risk,” the authors write.
Several authors disclosed financial ties to AstraZeneca, which funded the study.
Copyright © 2019 HealthDay. All rights reserved.